- Home
- EMBJ vs EXEL Comparison
EMBJ vs EXEL Comparison
Compare EMBJ & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EMBJ | EXEL |
|---|---|---|
| Founded | 1969 | 1994 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | EMBJ | EXEL |
|---|---|---|
| Price | $69.70 | $42.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $46.24 |
| AVG Volume (30 Days) | 1.0M | ★ 2.6M |
| Earning Date | 03-06-2026 | 02-10-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | 0.45 | ★ 2.38 |
| Revenue | ★ $7,746,796,250.00 | $2,288,218,000.00 |
| Revenue This Year | N/A | $9.47 |
| Revenue Next Year | $13.05 | $12.26 |
| P/E Ratio | $153.93 | ★ $17.83 |
| Revenue Growth | ★ 31.44 | 9.93 |
| 52 Week Low | $38.78 | $32.38 |
| 52 Week High | $80.75 | $49.62 |
Technical Indicators
Market Signals| Indicator | EMBJ | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 47.59 |
| Support Level | $68.16 | $42.17 |
| Resistance Level | $75.00 | $43.70 |
| Average True Range (ATR) | 2.22 | 1.37 |
| MACD | -1.10 | -0.15 |
| Stochastic Oscillator | 15.25 | 49.50 |
Price Performance
Historical ComparisonAbout EMBJ Embraer S.A.
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the various segments namely Commercial Aviation, Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.